Notification of major interest in Mediclinic International plc shares Mediclinic International plc (Incorporated in England and Wales) Company Number: 08338604 LSE Share Code: MDC JSE Share Code: MEI NSX Share Code: MEP ISIN: GB00B8HX8Z88 LEI: 2138002S5BSBIZTD5I60 ("Mediclinic", the "Company" or the "Group") 28 November 2017 Notification of Major Interest in Mediclinic International plc shares 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached (ii): Mediclinic International plc 1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate) Non-UK issuer 2. Reason for the notification (please mark the appropriate box or boxes with an "X") An acquisition or disposal of voting rights X An acquisition or disposal of financial instruments An event changing the breakdown of voting rights Other (please specify): 3. Details of person subject to the notification obligation Name Genesis Asset Managers, LLP City and country of registered office (if applicable) St. Peter Port, Guernsey 4. Full name of shareholder(s) (if different from 3.) Name N/A City and country of registered office (if applicable) 5. Date on which the threshold was crossed or reached: 27th November 2017 6. Date on which issuer notified (DD/MM/YYYY): 28th November 7. Total positions of person(s) subject to the notification obligation % of voting rights % of voting rights through financial Total of both in % Total number of attached to shares instruments (8.A + 8.B) voting rights of (total of 8. A) (total of 8.B 1 + 8.B 2) issuer Resulting situation on the date on which threshold 5.15% 5.15% 737,243,810 was crossed or reached Position of previ- ous notification (if applicable) 8. Notified details of the resulting situation on the date on which the threshold was crossed or reached A: Voting rights attached to shares Class/type of Number of voting rights % of voting rights shares ISIN code (if possi- Direct Indirect Direct Indirect ble) (Art 9 of Directive (Art 10 of Di- (Art 9 of Directive (Art 10 of Di- 2004/109/EC) rective 2004/109/EC) rective (DTR5.1) 2004/109/EC) (DTR5.1) 2004/109/EC) (DTR5.2.1) (DTR5.2.1) GB00B8HX8Z88 37,989,258 5.15% SUBTOTAL 8. A 37,989,258 5.15% B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a)) Number of voting Expira- rights that may be Type of financial tion Exercise/ acquired if the instru- % of voting instrument date Conversion Period ment is exercised/converted. rights SUBTOTAL 8. B 1 B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b)) Exercise/ Physical or Type of finan- Expiration Conversion cash Number of % of voting cial instrument date Period settlement voting rights rights SUBTOTAL 8.B.2 9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an "X") Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (under- lying) issuer Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity(xiv) (please add additional rows as necessary) % of voting rights % of voting rights if it through financial in- Total of both if it equals or is higher struments if it equals equals or is higher than the notifiable or is higher than the than the notifiable Name threshold notifiable threshold threshold 10. In case of proxy voting, please identify: Name of the proxy holder The number and % of voting rights held The date until which the voting rights will be held 11. Additional information Place of completion London, England Date of completion 28TH November 2017 Mediclinic has a primary listing on the Main Market of the LSE in the United Kingdom, with secondary listings on the JSE in South Africa and the NSX in Namibia. For further information please contact: Mediclinic International plc James Arnold, Head of Investor Relations ir@mediclinic.com +44 (0)20 3786 8181 Company Secretary, Link Company Matters Limited Victoria Dalby +44 (0)207 954 9600 Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom Website: www.mediclinic.com Corporate broker: Morgan Stanley & Co International plc JSE sponsor: RAND MERCHANT BANK (A division of FirstRand Bank Limited) NSX sponsor: Simonis Storm Securities (Pty) Ltd 4 Date: 29/11/2017 07:05:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on, information disseminated through SENS.